JPS63215631A - Wound remedy - Google Patents
Wound remedyInfo
- Publication number
- JPS63215631A JPS63215631A JP4759287A JP4759287A JPS63215631A JP S63215631 A JPS63215631 A JP S63215631A JP 4759287 A JP4759287 A JP 4759287A JP 4759287 A JP4759287 A JP 4759287A JP S63215631 A JPS63215631 A JP S63215631A
- Authority
- JP
- Japan
- Prior art keywords
- agent
- sugar
- inflammatory
- remedy
- potassium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 11
- 239000003242 anti bacterial agent Substances 0.000 claims abstract description 10
- 235000000346 sugar Nutrition 0.000 claims abstract description 9
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000000645 desinfectant Substances 0.000 claims abstract description 7
- 239000011591 potassium Substances 0.000 claims abstract description 7
- 229910052700 potassium Inorganic materials 0.000 claims abstract description 7
- 239000011782 vitamin Substances 0.000 claims abstract description 7
- 229940088594 vitamin Drugs 0.000 claims abstract description 7
- 229930003231 vitamin Natural products 0.000 claims abstract description 7
- 235000013343 vitamin Nutrition 0.000 claims abstract description 7
- 229940121363 anti-inflammatory agent Drugs 0.000 claims abstract description 6
- 239000002260 anti-inflammatory agent Substances 0.000 claims abstract description 6
- 230000003115 biocidal effect Effects 0.000 claims abstract description 6
- 108091005804 Peptidases Proteins 0.000 claims abstract description 5
- 210000000416 exudates and transudate Anatomy 0.000 claims abstract description 5
- 229940124549 vasodilator Drugs 0.000 claims abstract description 5
- 239000003071 vasodilator agent Substances 0.000 claims abstract description 5
- 230000002745 absorbent Effects 0.000 claims abstract description 4
- 239000002250 absorbent Substances 0.000 claims abstract description 4
- 150000003722 vitamin derivatives Chemical class 0.000 claims abstract description 3
- 238000011282 treatment Methods 0.000 claims description 13
- 206010052428 Wound Diseases 0.000 claims description 10
- 208000027418 Wounds and injury Diseases 0.000 claims description 10
- 239000003410 keratolytic agent Substances 0.000 claims description 4
- 239000004365 Protease Substances 0.000 claims description 3
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims 1
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 abstract description 8
- -1 corneum liquefacient Substances 0.000 abstract description 6
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 abstract description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 4
- 239000006071 cream Substances 0.000 abstract description 4
- 230000035876 healing Effects 0.000 abstract description 4
- 239000004615 ingredient Substances 0.000 abstract description 4
- GUBGYTABKSRVRQ-PICCSMPSSA-N D-Maltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 abstract description 3
- 102000035195 Peptidases Human genes 0.000 abstract description 3
- 239000000203 mixture Substances 0.000 abstract description 3
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 abstract description 2
- XMEVHPAGJVLHIG-FMZCEJRJSA-N chembl454950 Chemical compound [Cl-].C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H]([NH+](C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O XMEVHPAGJVLHIG-FMZCEJRJSA-N 0.000 abstract description 2
- 229960003276 erythromycin Drugs 0.000 abstract description 2
- 150000002772 monosaccharides Chemical class 0.000 abstract description 2
- 229960001699 ofloxacin Drugs 0.000 abstract description 2
- 229920001542 oligosaccharide Polymers 0.000 abstract description 2
- 150000002482 oligosaccharides Chemical class 0.000 abstract description 2
- 229960004989 tetracycline hydrochloride Drugs 0.000 abstract description 2
- 239000004599 antimicrobial Substances 0.000 abstract 2
- 230000002070 germicidal effect Effects 0.000 abstract 2
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 230000002797 proteolythic effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 15
- 229940124597 therapeutic agent Drugs 0.000 description 12
- 208000004210 Pressure Ulcer Diseases 0.000 description 7
- 230000000694 effects Effects 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000017423 tissue regeneration Effects 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- SBKRTALNRRAOJP-BWSIXKJUSA-N N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methylheptanamide (6S)-N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methyloctanamide sulfuric acid Polymers OS(O)(=O)=O.CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O.CC[C@H](C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O SBKRTALNRRAOJP-BWSIXKJUSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108010093965 Polymyxin B Proteins 0.000 description 2
- 229920000153 Povidone-iodine Polymers 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 229960003548 polymyxin b sulfate Drugs 0.000 description 2
- 229960001621 povidone-iodine Drugs 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 239000003206 sterilizing agent Substances 0.000 description 2
- RDEIXVOBVLKYNT-VQBXQJRRSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2-yl]o Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)C(C)N)N)[C@@H](N)C[C@H]1N.O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-VQBXQJRRSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 206010065929 Cardiovascular insufficiency Diseases 0.000 description 1
- 208000010445 Chilblains Diseases 0.000 description 1
- 206010008528 Chillblains Diseases 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 206010012444 Dermatitis diaper Diseases 0.000 description 1
- 208000003105 Diaper Rash Diseases 0.000 description 1
- 108010088842 Fibrinolysin Proteins 0.000 description 1
- 208000025309 Hair disease Diseases 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- RZMKWKZIJJNSLQ-UHFFFAOYSA-M carpronium chloride Chemical compound [Cl-].COC(=O)CCC[N+](C)(C)C RZMKWKZIJJNSLQ-UHFFFAOYSA-M 0.000 description 1
- 229950003631 carpronium chloride Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940001501 fibrinolysin Drugs 0.000 description 1
- 150000002303 glucose derivatives Chemical class 0.000 description 1
- 235000021552 granulated sugar Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000002239 ischium bone Anatomy 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- OIXVKQDWLFHVGR-WQDIDPJDSA-N neomycin B sulfate Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO OIXVKQDWLFHVGR-WQDIDPJDSA-N 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- UEJSSZHHYBHCEL-UHFFFAOYSA-N silver(1+) sulfadiazinate Chemical compound [Ag+].C1=CC(N)=CC=C1S(=O)(=O)[N-]C1=NC=CC=N1 UEJSSZHHYBHCEL-UHFFFAOYSA-N 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229960001322 trypsin Drugs 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 235000019195 vitamin supplement Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000003357 wound healing promoting agent Substances 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
【発明の詳細な説明】
(IIi業上の利用分野)
本発明は褥創などの創傷に対する治療剤に関し、特に電
気治療において効果のある創傷治療剤に関する。DETAILED DESCRIPTION OF THE INVENTION (Field of Industrial Use) The present invention relates to a therapeutic agent for wounds such as bedsores, and particularly to a wound therapeutic agent effective in electrical therapy.
(従来の技術及び解決すべき問題)
皮膚創傷の局所治療剤として使用されている薬剤はその
原因、程度その他の要因によって異るが、消毒剤、抗炎
症剤、蛋白分解酵素軟膏、浸出液吸収剤、ビタミン剤、
ホルモン剤などを目的に応じて混合した組成よりなる。(Prior Art and Problems to be Solved) Drugs used as topical treatments for skin wounds vary depending on the cause, severity, and other factors, but include disinfectants, anti-inflammatory agents, protease ointments, and exudate absorbents. , vitamin supplements,
It consists of a mixture of hormones and other drugs depending on the purpose.
しかし、深部組織に達する重度の火傷、熱傷、褥創、皮
膚潰傷、外傷などの皮膚損傷では強度の炎症反応1局所
循環障害感染などが生じ、単に上述の組成からなる創傷
治療剤のみでは治療に反応しないことが多い、このよう
な損傷部位では強度の炎症反応によって蛋白、水分、ミ
ネラル、ビタミンなどが喪失し、かつ局所循環障害によ
って組織修復に必須のそれらの物質が補給されにくいと
いう悪循環が繰り返されるため極めて難治性の潰傷を形
成することが多い、そして、このような皮膚損傷に対し
ては現在のところ外科的に植皮することが最善の治療法
として行なわれることが多いが、かする治療法は感染や
炎症反応を抑えたのちはじめて適応となるもので、初期
の薬物治療が極めて重要である。However, severe inflammatory burns that reach deep tissue, such as burns, bedsores, skin ulcers, and trauma, can cause severe inflammatory reactions, local circulation disorders, infections, etc. In such injured areas, proteins, water, minerals, vitamins, etc. are lost due to the strong inflammatory response, and local circulation disorders make it difficult for these substances essential for tissue repair to be replenished, creating a vicious cycle. This repeated occurrence often results in the formation of ulcers that are extremely difficult to treat, and although surgical skin grafting is currently often the best treatment for such skin injuries, These treatments are only applicable after the infection and inflammatory response have been suppressed, so early drug treatment is extremely important.
一方、糖が創傷に対して肉芽形成作用を有することが知
られ、創傷治療剤として使用されているが1重度の火傷
、熱傷、褥創などに対して単に潰傷部に塗布するような
治療法では未だ十分な効果を期待することはできなかっ
た。On the other hand, sugar is known to have a granulation-forming effect on wounds and is used as a wound treatment agent; The law was not yet expected to have sufficient effects.
(発明が解決しようとする問題点)
本発明者らは上述のような重度の火傷、熱傷、褥創など
に対しては炎症反応の抑制、感染の予防と治療、循環改
善、組織再生促進がその治療に必須であると共に局所循
環不全に伴う組織再生障害の改善が重要であり、そのた
め直接的に組織培養における培養液の成分と同等のもの
を損傷部位に与えて組織培養と同様の環境条件を作るこ
とであるとの見解のもとに種々検討した結果、肉芽形成
作用を有する糖と共にカリウムを存在させることにより
筋組織および神経組織の生存・再生に効果的であること
を見出し本発明を完成するにいたったのである。(Problems to be Solved by the Invention) The present inventors have proposed a method for suppressing inflammatory reactions, preventing and treating infections, improving circulation, and promoting tissue regeneration for severe burns, scalds, bedsores, etc. as described above. In addition to being essential for its treatment, it is also important to improve tissue regeneration disorders associated with local circulatory insufficiency.For this reason, the same environmental conditions as in tissue culture are achieved by directly applying ingredients equivalent to the culture medium in tissue culture to the injured area. As a result of various studies based on the idea that the purpose of the present invention is to produce It was finally completed.
(問題点を解決するための手段)
すなわち、本発明は糖とカリウムと殺菌消毒剤あるいは
抗生物質もしくは抗菌剤とからなる創傷治療剤であって
、更に必要に応じ、抗炎症剤、ビタミン剤、蛋白分解酵
素、蛋白分解酵素阻害剤、浸出液吸収剤、角質融解剤、
血管拡張剤、基剤を混和した創傷治療剤である。本発明
において使用する糖としてはブドウ糖、果実、マンノー
ズのような単糖類、麦芽糖、蔗糖などのオリゴ糖類なと
で、目的に応じて糖質および量を選択するが、通常、治
療剤100gに対し25g〜85g程度の量であり、ま
た、カリウムとしては治療剤100gに対し100.〜
400■程度の量である。そして、使用目的に応じ殺菌
消毒剤あるいは抗生物質もしくは抗菌剤を添加して治療
剤とするのであるが、更に、目的に応じ例えば、皮膚角
化症、各種皮膚炎、後天性色素異常症、湿疹、肌あれ、
鮫肌、シミ、にきび、ひび、あかぎれ、おむつかぶれ、
しもやけなどの皮膚障害に対しては角質溶解剤(サリチ
ル酸など)、ビタミン剤、消炎剤およびホルモン剤を、
白髪、脱毛症などの毛髪疾患に対して血管拡張剤、ビタ
ミン、ホルモン剤などの養毛、育毛剤を添加する。(Means for Solving the Problems) That is, the present invention is a wound treatment agent comprising sugar, potassium, and a bactericidal disinfectant, an antibiotic, or an antibacterial agent, and further contains an anti-inflammatory agent, a vitamin agent, Proteolytic enzymes, protease inhibitors, exudate absorbers, keratolytic agents,
A wound treatment agent containing a vasodilator and a base. The sugars used in the present invention include glucose, fruit, monosaccharides such as mannose, and oligosaccharides such as maltose and sucrose, and the sugar and amount are selected depending on the purpose, but usually per 100 g of the therapeutic agent. The amount is about 25g to 85g, and the amount of potassium is 100g per 100g of the therapeutic agent. ~
The amount is about 400 square meters. Depending on the purpose of use, sterilizing agents, antibiotics, or antibacterial agents are added to make therapeutic agents. , have skin,
Shark skin, spots, acne, cracks, chapping, diaper rash,
For skin disorders such as chilblains, use keratolytic agents (such as salicylic acid), vitamins, anti-inflammatory agents, and hormones.
Hair nourishing agents such as vasodilators, vitamins, and hormones are added to treat hair diseases such as gray hair and alopecia.
本発明で使用する消毒殺菌剤としてはポビドンヨード液
、(商品名イソジン液)、ポビドンヨードゲル(商品名
イソジンゲル)、スルファジアジン銀クリーム(商品名
ゲーベンクリーム)であり、その添加景は液の場合は5
〜10mQ、ゲルまたはクリームの場合は10〜30g
であり、抗菌剤としてはオフロキサシン(商品名タリビ
ット)1〜3■、抗生物質としてはエリスロマイシン、
塩酸テトラサイクリン、硫酸フラジオマイシン、硫酸ポ
リミキシンB、硫酸ゲンタマイシンであり、その量は0
.5〜3g(硫酸ポリミキシンBについては100万単
位)である。The disinfectants used in the present invention include povidone-iodine solution, (trade name: Isodine solution), povidone-iodine gel (trade name: Isodine gel), and sulfadiazine silver cream (trade name: Goeben cream).
~10mQ, 10-30g for gel or cream
The antibacterial agent is ofloxacin (trade name Talibit) 1-3, and the antibiotic is erythromycin,
Tetracycline hydrochloride, fradiomycin sulfate, polymyxin B sulfate, and gentamicin sulfate, the amount of which is 0.
.. 5 to 3 g (1 million units for polymyxin B sulfate).
本発明の治療剤の適用法としては患部に直接塗布するば
かりではなくサビオあるいは指サツクのような形態にし
てそのガーゼに含浸させることもでき、殊に、創傷治療
剤を含浸したガーゼを使用して電気治療を行なうとその
効果は大である。すなわち、負の電流刺激が化骨を促進
し、骨折がより早く治癒し、また、神経線維の成長を促
す事も知られているが、その際、本発明の治療剤と電気
刺激法とを併用すると、その作用機構はまだ解明されて
いないが、極めて早期の治癒が可能である。なお、電気
治療の際に使用する場合には電流の導通を良好にするた
め本発明の治療剤に塩化ナトリウムを添加することが好
ましく、その量としては治療剤100g当り約700■
程度である。The method of applying the therapeutic agent of the present invention is not only by applying it directly to the affected area, but also by impregnating it into gauze in the form of a sabio or finger pouch. In particular, gauze impregnated with the wound treatment agent can be used. Electrical therapy can be very effective. That is, it is known that negative current stimulation promotes bone formation, heals fractures more quickly, and promotes the growth of nerve fibers. When used in combination, extremely early healing is possible, although the mechanism of action has not yet been elucidated. When used in electrical therapy, it is preferable to add sodium chloride to the therapeutic agent of the present invention in order to improve current conduction, and the amount is approximately 700 μg per 100 g of the therapeutic agent.
That's about it.
更に1本発明では任意成分としてビタミン剤やdi−カ
ンフル、リドカイン、塩酸プロ力イン、グリテール、ジ
フェンヒドラミンなどの鎮痛剤および抗炎症剤やアラン
トインのような創傷治癒剤、また、サリチル酸、尿素の
ような角質融解剤やトリプシン、フィブリノリジンのよ
うな蛋白分解酵素やトラシノールのような蛋白分解酵素
阻害剤、ポリエチレングリコールのような浸出液吸収剤
やレシチン、塩酸ピロカルビン、塩化カルプロニウムな
どの血管拡張剤を添加することが出来る。Furthermore, in the present invention, optional ingredients include vitamins, analgesics such as di-camphor, lidocaine, prohydroline hydrochloride, Glytail, and diphenhydramine, anti-inflammatory agents, and wound healing agents such as allantoin, as well as salicylic acid and urea. Add keratolytic agents, proteases such as trypsin, fibrinolysin, protease inhibitors such as tracinol, exudate absorbents such as polyethylene glycol, and vasodilators such as lecithin, pirocarbin hydrochloride, and carpronium chloride. I can do it.
次に本発明を実施例をもって更に具体的に説明する。Next, the present invention will be explained in more detail with reference to Examples.
実施例1
足踵部にできた直径10a1の褥創に対し、ブドウ糖1
50g、イソジンゲル50g、イソジン液12mlおよ
びKCL400■とを均一に混合して治療剤約200g
を作り一日2回塗布したところ、約1ケ月で完治した。Example 1 Glucose 1 was applied to a bedsore with a diameter of 10a1 on the heel of the foot.
50g of Isodine gel, 12ml of Isodine solution and KCL400■ are uniformly mixed to make approximately 200g of therapeutic agent.
I made it and applied it twice a day, and it completely healed in about a month.
また、患者2例において仙骨部および腸骨稜部にできた
lai程度の小褥創にこのブドウ糖配合治療剤を適用し
たところ1週間程度で完治した。これは、KCLを添加
しない場合に比して約1.5〜2倍程度の速さで治癒し
たものと思われた。In addition, when this glucose combination therapeutic agent was applied to small bedsores of the size of lai in the sacrum and iliac crest in two patients, the wounds completely healed in about one week. This seemed to result in healing about 1.5 to 2 times faster than when KCL was not added.
実施例2
左殿部皮膚に直径5amの穴が開き、さらに皮下に直径
15G深さ53で坐骨まで達する空洞を形成した大きな
褥創に対し、グラニユー糖150 g 、インジンゲル
50g、イソジン液12+nlおよびKCL400■と
を均一に混合して治療剤約200gを作って褥創空洞内
に入れさらに一10μAの直流電流をここに流したとこ
ろ、約2ケ月後には皮膚開口部直径7■、皮下空洞直径
約2am深さ3aaにまで縮小し、糖と消毒剤のみを混
合した治療剤による治療法に比して約2倍程度の速さで
治癒していく傾向が認められた。Example 2 For a large bedsore in which a hole with a diameter of 5 am was made in the skin of the left buttock and a cavity with a diameter of 15 g and a depth of 53 that reached the ischium was formed under the skin, 150 g of granulated sugar, 50 g of insin gel, 12+nl of isodine solution, and 400 KCL were treated. About 200 g of the therapeutic agent was made by uniformly mixing the above ingredients, and the mixture was placed in the bedsore cavity and a direct current of 10 μA was passed there. After about 2 months, the skin opening diameter was 7 cm, and the subcutaneous cavity diameter was about 7 cm. It was observed that the tumor size decreased to a depth of 2 am and 3 aa, and that the tumor tended to heal about twice as fast as the treatment using a therapeutic agent containing only sugar and disinfectant.
(発明の効果)
以上述べたように、本発明は糖とカリウムと殺菌消毒剤
あるいは抗生物質もしくは抗菌剤との王者を混合使用す
ることにより相剰的に作用し、皮膚および毛髪などなど
の障害に対し広範に治癒作用を有し、その効果は極めて
大である。(Effects of the Invention) As described above, the present invention uses the combination of sugar, potassium, sterilizing agent, antibiotic, or antibacterial agent to act synergistically and cause problems such as skin and hair. It has a wide range of healing effects, and its effects are extremely large.
Claims (1)
は抗菌剤とからなり、更に必要に応じ、抗炎症剤、ビタ
ミン剤、蛋白分解酵素、蛋白分解酵素阻害剤、浸出液吸
収剤、角質融解剤、血管拡張剤、基剤を混和した創傷治
療剤 2、カリウム濃度が治療剤100gに対し100〜40
0mgである特許請求の範囲第1項記載の創傷治療剤[Scope of Claims] 1. Consisting of sugar, potassium, and a disinfectant, antibiotic, or antibacterial agent, and if necessary, an anti-inflammatory agent, a vitamin, a protease, a protease inhibitor, and an exudate absorbent. , a wound treatment agent 2 containing a keratolytic agent, a vasodilator, and a base, with a potassium concentration of 100 to 40 per 100 g of the treatment agent.
The wound treatment agent according to claim 1, which is 0 mg.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP62047592A JPH0692310B2 (en) | 1987-03-04 | 1987-03-04 | Wound healing agent |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP62047592A JPH0692310B2 (en) | 1987-03-04 | 1987-03-04 | Wound healing agent |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS63215631A true JPS63215631A (en) | 1988-09-08 |
JPH0692310B2 JPH0692310B2 (en) | 1994-11-16 |
Family
ID=12779520
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP62047592A Expired - Lifetime JPH0692310B2 (en) | 1987-03-04 | 1987-03-04 | Wound healing agent |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH0692310B2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004043473A1 (en) * | 2002-11-11 | 2004-05-27 | Kowa Co., Ltd. | Composition for restoring damaged skin |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6310731A (en) * | 1986-03-12 | 1988-01-18 | Kowa Co | Stable reparative pharmaceutical for damaged skin |
-
1987
- 1987-03-04 JP JP62047592A patent/JPH0692310B2/en not_active Expired - Lifetime
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6310731A (en) * | 1986-03-12 | 1988-01-18 | Kowa Co | Stable reparative pharmaceutical for damaged skin |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004043473A1 (en) * | 2002-11-11 | 2004-05-27 | Kowa Co., Ltd. | Composition for restoring damaged skin |
Also Published As
Publication number | Publication date |
---|---|
JPH0692310B2 (en) | 1994-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Modaghegh et al. | Use of phenytoin in healing of war and non‐war wounds: A pilot study of 25 cases | |
UA41989C2 (en) | Pharmaceutical composition in form of gel for treating skin diseases and method for treating infected skin | |
US20080020025A1 (en) | Composition for wound care and method of using same | |
DE69231486D1 (en) | COMPOSITION CONTAINING PDGF AND DEXAMETHASONE TO PROMOTE TISSUE REPAIR AND REGENERATION | |
US20100284951A1 (en) | Novel compositions for the treatment of wounds and skin care | |
US4735802A (en) | Topical dermatological composition and method of treatment | |
US5707972A (en) | Hydrophilic polysaccharide-based pharmaceutical perparation for external use | |
CA2411922A1 (en) | Composition for pain mediation and apparatus and method of use thereof | |
US6730323B1 (en) | Microclysmic gel for treatment of tissue trauma and burns | |
RU2636530C2 (en) | Pharmaceutical compositions for treatment of wounds and burns | |
RU2180856C1 (en) | Agent for wound healing | |
RU2423118C1 (en) | Method of treating trophic ulcers | |
Lindenbaum et al. | Serum-free cell culture medium induces acceleration of wound healing in guinea-pigs | |
JPS63215631A (en) | Wound remedy | |
Knight | Medical management of pressure sores | |
RU2577950C1 (en) | Method of stimulating healing dermal burns | |
JPH0472556B2 (en) | ||
JPH01299233A (en) | Remedy of skin wound | |
US10292997B2 (en) | Compositions and methods for stimulating wound healing | |
CN1209144C (en) | Externally applied medicine for treating burns and sore ulcer | |
WO2007143586A2 (en) | Composition for wound care and method of using same | |
US20030092682A1 (en) | Use of doxycycline for treatment of certain skin and mouth ailments | |
RU2342120C2 (en) | Method of contaminated wound treatment | |
RU2546030C1 (en) | Ichthyosin preparation | |
Jaffe et al. | Epidermal maturation arrest |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |